浏览全部资源
扫码关注微信
上海交通大学附属第六人民医院肿瘤内科,上海,200233
网络出版:2017-02-23,
纸质出版:2017-02-23
移动端阅览
刘子梅,沈 赞. 三阴性乳腺癌靶向治疗最新进展[J]. 中国癌症杂志, 2017, 27(1): 36-40.
刘子梅, 沈 赞. The latest developments in targeted therapy for triple-negative breast cancer[J]. China Oncology, 2017, 27(1): 36-40.
刘子梅,沈 赞. 三阴性乳腺癌靶向治疗最新进展[J]. 中国癌症杂志, 2017, 27(1): 36-40. DOI: 10.19401/j.cnki.1007-3639.2017.01.007.
刘子梅, 沈 赞. The latest developments in targeted therapy for triple-negative breast cancer[J]. China Oncology, 2017, 27(1): 36-40. DOI: 10.19401/j.cnki.1007-3639.2017.01.007.
三阴性乳腺癌(triple-negative breast cancer,TNBC)是一种特殊类型的乳腺癌,占乳腺癌总确诊的15%~20%。其雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)和人表皮生长因子受体(human epidermal growth factor receptor-2,HER-2)表达均阴性,具有独特的生物学特性和临床病理特征,肿瘤异质性很高,临床上具有复发高、转移早和预后差等特点。目前,临床上缺少有效的治疗手段。该综述介绍了TNBC的临床病理特征、分子亚型、几条重要的通路和靶点,以及目前各靶向药物临床试验研究进度,希望为今后TNBC的治疗提供新的临床思路。
Triple-negative breast cancer (TNBC) is a special type of breast cancer
accounting for 15%-20% of all diagnosed breast cancer cases. Its estrogen receptor (ER)
progesterone receptor (PR)
human epidermal growth factor receptor-2 (HER-2) expression is negative
with unique biological characteristics
clinicopathological features and tumor heterogeneity. Its clinical features include high incidence of relapse
early metastasis and poor prognosis. Currently
it lacks effective treatment. This review described the clinicopathological features of TNBC
its molecular subtypes
several important pathways and targets
as well as presented the progress in clinical studies of targeted drugs in the hope of generating new ideas for the treatment of TNBC in the future.
0
浏览量
3653
下载量
CSCD
关联资源
相关文章
相关作者
相关机构